Bellinda L. King-Kallimanis

Bellinda L. King-Kallimanis

Auto-generated profile, based on publicly available information

Bellinda L. King-Kallimanis

LUNGevity Foundation Institution, Bethesda, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2019 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
BKBellinda L King-Kallimanis
Bellinda L King-Kallimanis
LHLynn J Howie
Lynn J Howie
JRJessica K Roydhouse
Jessica K Roydhouse
HSHarpreet Singh
Harpreet Singh
MTMarc R Theoret
Marc R Theoret
PKPaul G Kluetz
Paul G Kluetz
Background: Patient-reported outcome measures can be used to capture the patient’s experience with disease and treatment. Immunotherapy agents including the anti-programmed death receptor-1/programmed death-ligand-1 inhibitor therapies have unique symptomatic side effects and patient-reported outcome data can help to characterize the benefits and burdens associated with therapy. Methods: We reviewed registration trials in the Food and Drug Administration database for five anti-programmed death receptor-1/programmed death-ligand-1 inhibitor therapies to characterize trial design and patient-reported outcome assessment strategy (cutoff 31 December 2017). We evaluated the patient-reported outcome measurement coverage of eight key symptoms related to adverse events reported in immunotherapy agent product labels (fatigue, diarrhea, cough, shortness of breath, musculoskeletal pain, rash, pruritus, and fever). Results: There were a total of 28 trials across seven disease types and one tumor agnostic indication reviewed, of which 17 were randomized and 25 were open label. Of the 28 trials, 21 contained patient-reported outcome measures and all 21 used >1 instrument. The most common instruments were the EuroQol five dimension (N = 19), and the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (N = 17). Disease-specific patient-reported outcome tools were included in nine trials (six lung, one head and neck, one melanoma and one renal cell). No trial used a patient-reported outcome strategy assessing all eight selected adverse events. Conclusion: Collection of patient-reported outcome data in anti-programmed death receptor-1/programmed death-ligand-1 inhibitor trials were variable and did not consistently assess important symptomatic adverse events. Use of a patient-reported outcome instrument with well-defined functional scales supplemented by item libraries to incorporate relevant symptomatic adverse events may allow for improved understanding of the patient experience while receiving therapy. These data, along with other clinical data such as hospitalizations and supportive care medication use can help inform the benefit–risk assessment for regulatory purposes.

30 April 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MMMeena N Murugappan
Meena N Murugappan
BKBellinda L King-Kallimanis
Bellinda L King-Kallimanis
GRGregory H Reaman
Gregory H Reaman
VBVishal Bhatnagar
Vishal Bhatnagar
EHErica G Horodniceanu
Erica G Horodniceanu
PKPaul G Kluetz
Paul G Kluetz
: Pediatric patient-reported outcome (PRO) data can help inform the US Food and Drug Administration’s (FDA’s) benefit-risk assessment of cancer therapeutics by quantifying symptom and functional outcomes from the patient’s perspective. : This study assessed use of PROs in commercial pediatric oncology trials submitted to the FDA for regulatory review. FDA databases were searched to identify pediatric oncology product applications approved between 1997 and 2020. Sponsor-submitted documents were reviewed to determine whether PRO data were collected, which instruments were used, and the quality of collected data (ie, sample size, completion rates, and use of fit-for-purpose instruments). The role of PROs in each trial (endpoint hierarchy) was also recorded in addition to whether any PRO endpoints were included in product labeling. : We reviewed 17 pediatric oncology applications, 4 of which included PRO data: denosumab, tisagenlecleucel, larotrectinib, and selumetinib. In these 4 instances, PROs served as exploratory endpoints and were not incorporated in product labeling. Trials that collected PRO data were phase II or phase I/II single-arm studies with sample sizes of 28 to 88 patients. Symptomatic adverse events (AEs) were characterized using clinician-reported Common Terminology Criteria for Adverse Events (CTCAE) without additional patient self-report. : PROs were infrequently used in pediatric cancer registration trials. When PROs were used, PRO data were limited by lack of a clear research objective and corresponding prospective statistical analysis plan. Contemporary PRO symptom libraries, such as the National Cancer Institute’s Pediatric PRO-CTCAE, may provide an opportunity to better evaluate the occurrence and impact of symptomatic AEs, from the patient’s perspective, in pediatric oncology trials.

15 May 2022 in Clinical Trials
Verified
Journal Article
Closed access
BKBellinda L King-Kallimanis
Bellinda L King-Kallimanis
VBVishal Bhatnagar
Vishal Bhatnagar
EHErica G Horodniceanu
Erica G Horodniceanu
TCTing-Yu Chen
Ting-Yu Chen
PKPaul G Kluetz
Paul G Kluetz
Objective: Although patient-reported symptoms and side effects are increasingly measured in cancer clinical trials, an appropriate assessment frequency has not yet been established. To determine whether differences in assessment frequency affect the apparent incidence and severity of patient-reported symptoms using two well-established patient-reported outcome measures used within the same clinical trial. Methods: We examined patient-reported outcome results from AURA3 (NCT02151981), a randomized open-label study comparing Tagrisso (osimertinib) with platinum-based chemotherapy in patients with previously treated estimated glomerular filtration rate/T790M mutation-positive metastatic non-small cell lung cancer. The outcome of interest was the proportion of patients in each arm that reported worsening of nausea, vomiting, fatigue, diarrhea, constipation, and appetite loss from baseline measured using the patient-reported outcome—common terminology criteria for adverse event (weekly) or European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (every 6 weeks). Results: Similar trends were observed for all six symptoms investigated. Using nausea in the chemotherapy arm as an example, 76% of patients reported any worsening from baseline based on weekly patient-reported outcome—common terminology criteria for adverse event assessments. When using an every 6-week assessment of Quality of Life Questionnaire Core 30 nausea and restricting analysis to an every 6-week assessment for patient-reported outcome—common terminology criteria for adverse event nausea, the proportion of chemotherapy arm patients reporting any worsening of nausea was 40% for both measures. Across the six patient-reported symptomatic adverse events, we observed differential proportions when comparing frequent versus sparse assessment. Conclusion: This analysis demonstrates that more frequent assessment of patient-reported symptomatic adverse events will lead to improved detection, and therefore a more complete understanding of the tolerability of experimental anti-cancer therapies.

1 August 2018 in Seminars in Oncology
Verified
Journal Article
Closed access
BKB.L. King-Kallimanis
B.L. King-Kallimanis
BKB. Kanapuru
B. Kanapuru
GBG.M. Blumenthal
G.M. Blumenthal
MTM.R. Theoret
M.R. Theoret
PKP.G. Kluetz
P.G. Kluetz

25 February 2020 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
BKBellinda L. King-Kallimanis
Bellinda L. King-Kallimanis
TWTanya Wroblewski
Tanya Wroblewski
VKVirginia Kwitkowski
Virginia Kwitkowski
RCR. Angelo De Claro
R. Angelo De Claro
TGThomas Gwise
Thomas Gwise
PKPaul G. Kluetz
Paul G. Kluetz

10 March 2020 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
JRJessica K Roydhouse
Jessica K Roydhouse
BKBellinda L King-Kallimanis
Bellinda L King-Kallimanis
PRPourab Roy
Pourab Roy
CWChana Weinstock
Chana Weinstock
DKDanielle Krol
Danielle Krol
PKPaul G Kluetz
Paul G Kluetz
Background: Patient reports of expected treatment side effects are increasingly collected as part of the assessment of patient experience in clinical trials. A global side effect item that is patient-reported has the potential to inform overall tolerability. Therefore, the aim of this study was to examine the completion and distribution of such a global single-item measure of side effect burden in five cancer clinical trials. Methods: Data from five trials from internal Food and Drug Administration databases that included the Functional Assessment of Cancer Therapy–General single-item measure of overall side effect burden (i.e. impact on degree of bother) were analyzed. Completion rates for the side effect bother item, items adjacent to this item, and two non-adjacent items on the Functional Assessment of Cancer Therapy–General that are related to health-related quality of life were calculated at the baseline assessment and at the 3-month assessment. To evaluate the distribution, the percentage of patients reporting high levels (quite a bit or very much bother) of side effect bother at baseline and 3 months was assessed. Results: Completion rates for all items were at least 80% regardless of time point or trial population. However, in three of the five trials, completion rates for the side effect bother item were lower at baseline compared to adjacent and non-adjacent items. This difference was not observed at 3 months. Up to 9.4% of patients reported high levels of side effect bother at baseline. Conclusion: Patients may enter trials already reporting some bother from side effects. This can make interpretation of results with respect to the investigational agent under study challenging. Patients may skip an item evaluating side effect bother at baseline, suggesting some difficulty with interpretation of what is being asked. Further study of the wording and utility of a baseline side effect bother assessment is warranted.